The E-cadherin repressor Snail is associated with lower overall survival of ovarian cancer patients
Standard
The E-cadherin repressor Snail is associated with lower overall survival of ovarian cancer patients. / Blechschmidt, K; Sassen, S; Schmalfeldt, B; Schuster, T; Höfler, H; Becker, K-F.
in: BRIT J CANCER, Jahrgang 98, Nr. 2, 29.01.2008, S. 489-95.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - The E-cadherin repressor Snail is associated with lower overall survival of ovarian cancer patients
AU - Blechschmidt, K
AU - Sassen, S
AU - Schmalfeldt, B
AU - Schuster, T
AU - Höfler, H
AU - Becker, K-F
PY - 2008/1/29
Y1 - 2008/1/29
N2 - Epithelial ovarian cancer is the leading cause of death among female genital malignancies. Reduced expression of the cell adhesion molecule E-cadherin was previously shown to be associated with adverse prognostic features. The role of the E-cadherin repressor Snail in ovarian cancer progression remains to be elucidated. We analysed formalin-fixed and paraffin-embedded specimens of 48 primary ovarian tumours and corresponding metastases for expression of E-cadherin and Snail by immunohistochemistry. We found a significant correlation between E-cadherin expression in primary cancers and their corresponding metastases (P<0.001). This correlation was found for Snail expression as well (P<0.001). There was a significant (P=0.008) association of reduced E-cadherin expression in primary ovarian cancer with shorter overall survival. Similarly, Snail expression in corresponding metastases (P=0.047) was associated with reduced overall survival of the patients. Additionally, the group of patients showing reduced E-cadherin and increased Snail immunoreactivity in primary tumours and corresponding metastases, respectively, had a significantly higher risk of death (P=0.002 and 0.022, respectively) when compared to the patient group with the reference expression profile E-cadherin positive and Snail negative. Taken together, the results of our study show that the E-cadherin repressor Snail is associated with lower overall survival of ovarian cancer patients.
AB - Epithelial ovarian cancer is the leading cause of death among female genital malignancies. Reduced expression of the cell adhesion molecule E-cadherin was previously shown to be associated with adverse prognostic features. The role of the E-cadherin repressor Snail in ovarian cancer progression remains to be elucidated. We analysed formalin-fixed and paraffin-embedded specimens of 48 primary ovarian tumours and corresponding metastases for expression of E-cadherin and Snail by immunohistochemistry. We found a significant correlation between E-cadherin expression in primary cancers and their corresponding metastases (P<0.001). This correlation was found for Snail expression as well (P<0.001). There was a significant (P=0.008) association of reduced E-cadherin expression in primary ovarian cancer with shorter overall survival. Similarly, Snail expression in corresponding metastases (P=0.047) was associated with reduced overall survival of the patients. Additionally, the group of patients showing reduced E-cadherin and increased Snail immunoreactivity in primary tumours and corresponding metastases, respectively, had a significantly higher risk of death (P=0.002 and 0.022, respectively) when compared to the patient group with the reference expression profile E-cadherin positive and Snail negative. Taken together, the results of our study show that the E-cadherin repressor Snail is associated with lower overall survival of ovarian cancer patients.
KW - Adult
KW - Aged
KW - Aged, 80 and over
KW - Cadherins
KW - Carcinoma
KW - Disease Progression
KW - Down-Regulation
KW - Female
KW - Follow-Up Studies
KW - Gene Expression Regulation, Neoplastic
KW - Humans
KW - Matched-Pair Analysis
KW - Middle Aged
KW - Neoplasm Metastasis
KW - Ovarian Neoplasms
KW - Repressor Proteins
KW - Survival Analysis
KW - Transcription Factors
U2 - 10.1038/sj.bjc.6604115
DO - 10.1038/sj.bjc.6604115
M3 - SCORING: Journal article
C2 - 18026186
VL - 98
SP - 489
EP - 495
JO - BRIT J CANCER
JF - BRIT J CANCER
SN - 0007-0920
IS - 2
ER -